Englumafusp alfa

PreclinicalSmall molecule

Roche

Englumafusp alfa is one of 9 small molecule programs targeting Lymphoma, Non-Hodgkin. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, Non-HodgkinActive, not recruiting

Lymphoma, Non-HodgkinPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Lymphoma, Non-Hodgkin

#DrugCompanyPhaseTrials

Gazyva

Roche

Preclinical

1 2

COLUMVI

Roche

Preclinical

1 3

Actemra

CCelltrion

Preclinical

1 4

MK-1045

Merck & Co.

Preclinical

1 5

JNJ-80948543

Johnson & Johnson

Phase 1

3 6

JNJ-87801493

Johnson & Johnson

Phase 1

2 7

JNJ-75348780

Johnson & Johnson

Phase 1

2 8

Prizloncabtagene Autoleucel

Johnson & Johnson

Preclinical

1 9

Englumafusp alfa

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Lymphoma, Non-Hodgkin

NCT04077723

Clinical

Trials by Indication[1]

Lymphoma, Non-Hodgkin1 trial

An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04077723·498 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Englumafusp alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Englumafusp alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Englumafusp alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Roche

Englumafusp alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Lymphoma, Non-Hodgkin1 trial

References

Drug Info

Quick Facts

Related News